2. Search Result
Search Result
Results for "

extravasation

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

7

Peptides

2

Inhibitory Antibodies

1

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0229
    Zolmitriptan

    BW-311C90; 311C90

    		 5-HT Receptor Endogenous Metabolite Neurological Disease
    Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist that can cross the blood-brain barrier, with Kis of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine .
    Zolmitriptan
  • HY-B0197A
    Naratriptan hydrochloride
    2 Publications Verification

    GR-85548A hydrochloride

    		 5-HT Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Naratriptan (GR-85548A) hydrochloride is a selective 5-HT1B/1D receptor agonist. Naratriptan hydrochloride is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC50=0.11 μM for dog basilar artery). Naratriptan hydrochloride also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan hydrochloride is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .
    Naratriptan hydrochloride
  • HY-P99336
    Enlimomab

    BI-RR 0001; Anti-Human IL6 Recombinant Antibody

    		 Integrin Neurological Disease Inflammation/Immunology
    Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .
    Enlimomab
  • HY-P991224
    CAP-100

    		CCR Inflammation/Immunology Cancer
    CAP-100 is a monoclonal antibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL .
    CAP-100
  • HY-14406A
    L-733060 hydrochloride
    1 Publications Verification

    		 Neurokinin Receptor Neurological Disease Cancer
    L-733060 hydrochloride is a selective neurokinin-1 (NK-1) receptor antagonist. L-733060 hydrochloride mainly regulates pain transmission and neural plasticity by blocking the binding of Substance P (P substance) to the NK-1 receptor. L-733060 hydrochloride blocks the promoting effect of Substance P on long-term potentiation (LTP) in the hippocampus. L-733060 hydrochloride reverses the orofacial hyperalgesia induced by experimental occlusal interference (EOI) in rats. L-733060 hydrochloride hydrochloride inhibits neurogenic plasma extravasation at a dose that does not cause adverse cardiovascular effects in rodents, and also acts as an anti-tumor agent. L-733060 hydrochloride can be used for the study of chronic orofacial pain .
    L-733060 hydrochloride
  • HY-172458
    Z-3578
    1 Publications Verification

    		 Mas-related G-protein-coupled Receptor (MRGPR) TNF Receptor Inflammation/Immunology
    Z-3578 is an orally active small-molecule antagonist of MrgX2 with potent antipseudoallergic activity, exhibiting a KD value of 729 nM. Z-3578 effectively inhibits mast cell degranulation induced by substance P (SP) and C48/80, suppresses the release of β-hexosaminidase, significantly reduces the release of histamine and TNF-α, and decreases intracellular calcium flux. In a mouse pseudoallergy model, Z-3578 significantly alleviates paw swelling and dye extravasation, and reduces serum histamine levels. Z-3578 can be used for the study of pseudoallergic reactions .
    Z-3578
  • HY-B0197
    Naratriptan

    GR-85548A

    		 5-HT Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Naratriptan is an orally active and selective 5-HT1B/1D receptor agonist. Naratriptan is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC50=0.11 μM for dog basilar artery). Naratriptan also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .
    Naratriptan
  • HY-103131
    PNU-142633

    		5-HT Receptor Neurological Disease
    PNU-142633 is a high affinity, selective and orally active 5-HT1D receptor agonist with Kis of 6 nM and > 18 000 nM for human 5-HT1D receptor and human 5-HT1B receptor, respectively. PNU-142633 has anti-migraine efficacy .
    PNU-142633
  • HY-P1118
    Ac9-25

    		Formyl Peptide Receptor (FPR) Inflammation/Immunology
    Ac9-25, a N-terminal peptide of Annexin I, acts as a formyl peptide receptor (FPR) agonist and activates the neutrophil NADPH oxidase through FPR .
    Ac9-25
  • HY-19443
    UCB-35440

    		Histamine Receptor Lipoxygenase Inflammation/Immunology
    UCB-35440 is an orally active histamine H1 receptor antagonist and 5-lipoxygenase inhibitor. UCB-35440 can be used for the research of dermatologic inflammatory conditions .
    UCB-35440
  • HY-103132
    PNU109291

    		5-HT Receptor Neurological Disease
    PNU109291 is a potent and selective 5-HT1D agonist. PNU109291 reduces dural plasma extravasation evoked by trigeminal ganglion stimulation .
    PNU109291
  • HY-14406
    L-733060

    		Neurokinin Receptor Neurological Disease Cancer
    L-733060 is a selective neurokinin-1 (NK-1) receptor antagonist. L-733060 mainly regulates pain transmission and neural plasticity by blocking the binding of Substance P (P substance) to the NK-1 receptor. L-733060 blocks the promoting effect of Substance P on long-term potentiation (LTP) in the hippocampus. L-733060 reverses the orofacial hyperalgesia induced by experimental occlusal interference (EOI) in rats. L-733060 hydrochloride inhibits neurogenic plasma extravasation at a dose that does not cause adverse cardiovascular effects in rodents, and also acts as an anti-tumor agent. L-733060 can be used for the study of chronic orofacial pain .
    L-733060
  • HY-B0197AS
    Naratriptan-d3 hydrochloride

    GR-85548A d3

    		 5-HT Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Naratriptan-d3 (GR-85548A-d3) is the deuterium labeled Naratriptan hydrochloride (HY-B0197A). Naratriptan hydrochloride is a selective 5-HT1B/1D receptor agonist. Naratriptan hydrochloride is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC50=0.11 μM for dog basilar artery). Naratriptan hydrochloride also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan hydrochloride is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .
    Naratriptan-d3 hydrochloride
  • HY-19252
    GR-4991W93

    		5-HT Receptor Neurological Disease
    GR-4991W93 is an orally active partial agonist against 5HT1B/1D receptor, with pIC50 values of 6.95 and 7.80 against 5HT1B and 5HT1D, respectively. GR-4991W93 demonstrates potent inhibition of electrically evoked plasma extravasation in the guinea pig. GR-4991W93 can be used for migraine research .
    GR-4991W93
  • HY-P10268
    Neuropeptide K (human, porcine, rat)

    		Neurokinin Receptor Cardiovascular Disease Neurological Disease
    Neuropeptide K, human, porcine, rat exhibits bioactivity in gallbladder contraction, protein extravasation, hypotension and brcnchial smooth muscle spasm. Neuropeptide K, human, porcine, rat is concentrated in brain and acts as tachykinin neuromessenger .
    Neuropeptide K (human, porcine, rat)
  • HY-P1118A
    Ac9-25 TFA

    		Formyl Peptide Receptor (FPR) Inflammation/Immunology
    Ac9-25 TFA, a N-terminal peptide of Annexin I, acts as a formyl peptide receptor (FPR) agonist and activates the neutrophil NADPH oxidase through FPR .
    Ac9-25 TFA
  • HY-117952
    L 743310

    		Neurokinin Receptor Neurological Disease
    L 743310 is a non-peptide, selective antagonist of the human neurokinin hNK1 receptor, with high affinity for primate and cloned human hNK1 receptors and lower affinity for rodent NK1 receptors. L 743310 inhibits resiniferatoxin-induced plasma protein extravasation in guinea pig esophagus. L 743310 has a dose-dependent inhibitory effect on cisplatin-induced emesis .
    L 743310
  • HY-135487
    Sibenadet

    AR-C68397AA free base; AR-C68397XX

    		 Dopamine Receptor Adrenergic Receptor Neurological Disease
    Sibenadet (AR-C68397AA free base) is a dual dopamine D2/β2-adrenoceptor agonist with selective β2-adrenoceptor agonism. Sibenadet inhibits capsaicin-induced plasma protein extravasation in rat trachea. Sibenadet suppresses edema from sensory nerve fiber activation by activating β2-adrenoceptor. Sibenadet is promising for research of chronic obstructive pulmonary disease (COPD) .
    Sibenadet
  • HY-118378
    ZD6021

    		Neurokinin Receptor Neurological Disease Endocrinology
    ZD6021 is an orally active Neurokinin 1 Receptor antagonist, with Ki values of 0.12 nM for NK1 and 0.62 nM for NK2. At a concentration of 100 nM, ZD6021 has a pKB value of 8.9 for human pulmonary artery NK1 receptors, and a pKB value of 7.3 for human bronchial NK2 receptors. ZD6021 effectively reduces ASMSP-induced plasma protein extravasation in guinea pigs, with an ED50 of 0.5 mg/kg, and also decreases NK2 mediated bronchoconstriction, with an ED50 of 13 mg/kg .
    ZD6021
  • HY-B0197S
    Naratriptan-d3

    GR-85548A-d3-1

    		 5-HT Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Naratriptan-d3 (GR-85548A-d3) is the deuterium labeled Naratriptan (HY-B0197). Naratriptan is a selective 5-HT1B/1D receptor agonist. Naratriptan is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC50=0.11 μM for dog basilar artery). Naratriptan also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .
    Naratriptan-d3
  • HY-B0197AR
    Naratriptan hydrochloride (Standard)

    GR-85548A hydrochloride (Standard)

    		 Reference Standards 5-HT Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Naratriptan (GR-85548A) hydrochloride (Standard) is the analytical standard of Naratriptan hydrochloride (HY-B0197A). This product is intended for research and analytical applications. Naratriptan is a selective 5-HT1B/1D receptor agonist. Naratriptan is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC50=0.11 μM for dog basilar artery). Naratriptan also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .
    Naratriptan hydrochloride (Standard)
  • HY-P11647A
    RPARPAR acetate

    		Complement System Cancer
    RPARPAR acetate is a CendR tumor-penetrating peptide. RPARPAR acetate directly binds to the NRP-1 and NRP-2 receptors on the surface of tumor cells, triggering cellular internalization, vascular extravasation, and penetration into tumor tissues. RPARPAR acetate serves as an efficient ligand for targeting nanocarriers to NRP-1-positive tumors. RPARPAR acetate is applicable in research on tumor targeting and drug delivery .
    RPARPAR acetate
  • HY-P11647
    RPARPAR

    		Complement System Cancer
    RPARPAR is a CendR tumor-penetrating peptide. RPARPAR directly binds to the NRP-1 and NRP-2 receptors on the surface of tumor cells, triggering cellular internalization, vascular extravasation, and penetration into tumor tissues. RPARPAR serves as an efficient ligand for targeting nanocarriers to NRP-1-positive tumors. RPARPAR is applicable in research on tumor targeting and drug delivery .
    RPARPAR
  • HY-123497
    R116031

    		Neurokinin Receptor Neurological Disease
    R116031 is a selective Neurokinin-1 (NK-1) receptor antagonist with a Ki of 0.45 nM for human NK-1 receptor. R116031 inhibits Substance P (HY-P0201)-induced peripheral effects (skin reactions and plasma extravasation in guinea pigs) and a central effect (thumping in gerbils).R116031 labeled with 3H significantly accumulate in the striatum, olfactory tubercule, olfactory bulb and locus coeruleus in gerbils models. R116031 can be used as a positron emission tomography (PET) ligand for PET imaging .
    R116031

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: